Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
about
Megakaryocytes, malignancy and bone marrow vascular nichesCurrent status of antiangiogenic factors.The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia.Thalidomide: present and future in multiple myeloma.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.Mechanism and Function of Angiogenin in Hematopoietic Malignancy.The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression.PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports.Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas.Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?MRI and PET of bone marrow in lymphoproliferative diseases.Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma.The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas.Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis.Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model
P2860
Q26862087-F4677721-24EA-4C96-90A1-FE652BE96066Q33962049-7BA7E6F5-F341-488A-A6AC-40C07F4821C0Q34422363-78389609-6A83-4AC9-A3CC-17EA97AA520DQ35104372-65B6D0CA-5377-48F3-889F-C603230E5497Q36066131-D50AB0F2-1449-436E-A0AC-FE632377A547Q36429727-31414C94-2CF8-42E0-9349-9F2C8E9B0D8FQ36490167-E7A4A1F3-56D8-4B54-85CC-DAA185ADB002Q38366707-7B1EC0BC-F6D6-46AE-9BF3-BB7886506378Q38615755-59191E43-74BF-48CE-9BF2-A945390B9EAEQ39556264-25B41890-61DB-4A89-AE33-1F01A8582928Q40071735-814D33EE-07DE-4878-9400-366FBD161316Q40586132-F506C6AF-9947-461B-81D4-E56799BACFFFQ40706795-82122BFE-65C5-4777-987F-0FB79F4EA2D7Q40734914-1334F8A3-2CD1-4980-98EF-C196E29690D2Q43885598-F77A8CCD-FCEB-478F-B8CE-336CDBBFAFE7Q44163682-04AC2857-C2A4-4233-9C25-4089459DEF3DQ44563437-E0224007-D91D-410E-A4D8-E84BD581C81DQ46193990-7CAA6FBE-A8C8-4CEF-B08E-8CE7E83C6BBBQ46346001-3241C282-69CE-4621-9D02-BC297EDBA689Q46568714-414E759C-508F-439F-8D87-D4B659CDCD13Q51733952-6E7E224B-A332-43C4-B535-49CBC8BD85D3Q51810088-79AA5D42-6CFC-4AD3-9707-A2D054F63731Q57530074-47DE908E-6E86-4B7C-8009-EE3597769891
P2860
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
@en
type
label
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
@en
prefLabel
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
@en
P2093
P2860
P1433
P1476
Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
@en
P2093
P2860
P356
10.3109/10428199509054750
P577
1995-12-01T00:00:00Z